Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;8(11):1149-1156.
doi: 10.1002/sctm.18-0285. Epub 2019 Jul 21.

Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis

Kenneth Mautner  1   2 , Robert Bowers  1   2 , Kirk Easley  3 , Zachary Fausel  2 , Ryan Robinson  1
Affiliations

Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis

Kenneth Mautner et al. Stem Cells Transl Med. 2019 Nov.

Abstract

This study aimed to determine whether autologous orthobiologic tissue source affects pain and functional outcomes in patients with symptomatic knee osteoarthritis (OA) who received microfragmented adipose tissue (MFAT) or bone marrow aspirate concentrate (BMAC) injection. We retrospectively reviewed prospectively collected data from patients who received BMAC or MFAT injection for symptomatic knee OA. Patients completed baseline and follow-up surveys. Each survey included the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, Emory Quality of Life (EQOL) questionnaire, and Visual Analog Scale (VAS) for pain. The follow-up responses were compared with baseline for all patients and between BMAC and MFAT groups. A total of 110 patients met inclusion criteria, with 76 patients (BMAC 41, MFAT 35) and 106 knees (BMAC 58, MFAT 48) having appropriate follow-up data. The BMAC group included 17 females and 24 males, with a mean age of 59 ± 11 years. The MFAT group included 23 females and 12 males, with a mean age of 63 ± 11 years. Minimum follow-up time was 0.5 years. Mean follow-up time was 1.80 ± 0.88 years for BMAC and 1.09 ± 0.49 years for MFAT. Both groups had significant improvement in EQOL, VAS, and all KOOS parameters preprocedure versus postprocedure (p < .001). There was not a significant difference when comparing postprocedure scores between groups (p = .09, .38, .63, .94, .17, .15, .70, respectively). These data demonstrate significant improvement in pain and function with both MFAT and BMAC injections in patients with symptomatic knee OA without a significant difference in improvement when comparing the two autologous tissue sources. Stem Cells Translational Medicine 2019;8:1149-1156.

Keywords: Adipose; Adipose stem cells; Adult stem cells; Arthritis; Bone marrow; Mesenchymal stem cells; Stem cells.

PubMed Disclaimer

Conflict of interest statement

K.M. currently receives book royalties from Elsevier and McGraw‐Hill, and is a minor investor in Tenex Health. The other authors indicated no potential conflicts of interest.

Figures

Figure 1
Figure 1
Responder rate by Kellgren–Lawrence grade.
Figure 2
Figure 2
Knee Injury and Osteoarthritis Outcome Score at baseline and follow‐up.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Osteoarthritis (OA; CDC website). Available at https://www.cdc.gov/arthritis/basics/osteoarthritis.htm. Accessed April 3, 2018.
    1. Kotlarz H, Gunnarsson CL, Fang H, et al. Insurer and out‐of‐pocket costs of osteoarthritis in the US: Evidence from national survey data. Arthritis Rheum 2009;60:3546–3553. - PubMed
    1. Nguyen US, Zhang Y, Zhu Y, et al. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: Survey and cohort data. Ann Intern Med 2011;155:725–732. - PMC - PubMed
    1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163–2196. - PMC - PubMed
    1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26–35. - PMC - PubMed